PracticeUpdate: Conference Series - The Best of ICIEM 2017

Not too rare to care The rarity of MPS counts against early diagnosis 1–3 Collectively affecting only one in 22,500 births, 3 the very rarity of mucopolysaccharidoses (MPSs), together with a varied and subtle clinical presentation, make early diagnosis difficult. 1,2,4 This can expose patients to irreversible organ damage that treatment may prevent. 1,2,4 To assist in the diagnosis of rare diseases like MPS, Sanofi Genzyme is providing paediatricians with access to a highly-sophisticated differential checklist built on a database of 6,000 diseases.

To register for FREE* access visit RDaware.com.au

*Free access until 14th May 2018. References: 1. Meikle PJ et al. JAMA 1999; 281: 249-54. 2. Muenzer J. J Pediatr 2004; 144: S27-S34. 3. Muenzer J et al. Pediatrics 2009; 123 (1): 19-29. 4. Burton BK, Giugliani R. Eur J Pediatr 2012; 171: 631-9. sanofi-aventis Australia Pty Ltd trading as Sanofi Genzyme. ABN 31 008 558 807. Talavera Corporate Centre Building D 12-24 Talavera Road. Macquarie Park, NSW 2113. GZANZ.ALDU.15.01.0025(1). July 2017. MPS0024